NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide personalized cancer immunotherapy. The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics...